GIST

Stivarga for GIST tumors

GIST(Gastrointenstinal Stromal Tumor)  is the most common form of sarcoma in the gastrointestinal tract. There are thought to be 4,000-5,000 new cases of GIST diagnosed each year in the USA,  about 1,500 of them metastatic. Two treatments for GIST has been recently FDA approved. Recently, FDA also approved regorefanib, Stivarga, for colon cancer, based on the CORRECT trial. The application for approval is for GIST is now pending before the FDA.

Read more
Regorefanib for GIST (Gastrointenstinal Stromal Tumor) – pro

GIST is the most common form of sarcoma that is found in the gastrointestinal tract. There are thought to be 4,000-5,000 new cases of GIST diagnosed each year in the USA, of them about 1,500 metastatic. New treatments for GIST continue to appear. The most recent candidate for accelerated approval before FDA is regorefanib, recenlty approved as Stivarga for colon cancer. The application for approval is based on the recent GRIP study of 132 patients

Read more
Surveillance for GIST

Gastrointestinal stromal tumor (GIST), a type of tumor usually found in the stomach or small intestine,. It is unique because it responds to newer biologicals, such as GLeevec or Tasigna.  Although there are those who recommend routine surveillance for this difficult to follow cancer(Choi et al), unfortuntely, prospective data and a consensus for guidelines concerning the screening of asymptomatic high risk patients and surveillance following multidisciplinary

Read more

Fatal error: Call to undefined function fw_blog_pagination() in /home/content/43/9379243/html/wp-content/themes/wisdom/blog_category.php on line 39